<DOC>
	<DOCNO>NCT00002805</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient acute myeloid leukemia myelodysplastic syndrome first relapse achieve first remission .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Acute Myeloid Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity , remission rate , event-free survival , overall survival follow induction cytarabine/mitoxantrone ( ARA-C/DHAD ) , intensification ARA-C etoposide ( VP-16 ) , consolidation cladribine ( 2-CdA ) VP-16 patient acute myeloid leukemia ( AML ) secondary , first relapse , fail initial remission induction therapy . II . Compare remission induction rate event-free survival trial prior second-line study ( i.e. , protocols CCG-243 , CCG-201 , CCG-261P ) . III . Compare survival patient trial survival patient relapse fail achieve initial complete remission ( CR ) previous front-line AML trial ( i.e. , protocols CCG-251 , CCG-213 , CCG-2861 , CCG-2891 ) . IV . Determine frequency prognostic significance mdr1 gene expression p53 , topoisomerase II , deoxycytidine kinase gene mutation patient . V. Determine disease-free overall survival patient achieve CR study relation post-intensification therapy receive ( i.e. , bone marrow transplantation , chemotherapy , therapy ) . VI . Determine frequency degree abnormal cardiac function echocardiogram MUGA 1 5 year patient treat mitoxantrone follow anthracycline therapy initial treatment . VII . Provide control arm evaluate safety use phase I II agent `` upfront window '' approach plan future CCG study . VIII . Determine toxicity , remission rate , event-free survival , overall survival patient fail achieve CR ARA-C/DHAD induction treat 2-CdA/VP-16 . IX . Determine biologic characteristic , toxicity , remission rate , event-free survival , overall survival follow treatment regimen patient develop AML second malignancy . OUTLINE : Patients achieve M1/M2a marrow follow Induction proceed Salvage Induction ; others proceed Intensification . Patients receive Consolidation therapy Regimen A , B , C accord investigator 's choice . The following acronym use : ARA-C Cytarabine , NSC-63878 2-CdA Cladribine ( 2-Chlorodeoxyadenosine ) , NSC-105014 DHAD Mitoxantrone , NSC-301739 G-CSF Filgrastim , NSC-614629 HC Hydrocortisone , NSC-10483 HD High Dose MTX Methotrexate , NSC-740 PBSC Peripheral Blood Stem Cells TBI Total-Body Irradiation TIT Triple Intrathecal Therapy ( IT ARA-C/IT HC/IT MTX ) VP-16 Etoposide , NSC-141540 INDUCTION : 2-Drug Combination Chemotherapy plus CNS Prophylaxis/Therapy . ARA-C/DHAD ; G-CSF ; plus IT ARA-C , CNS disease entry , TIT . SALVAGE INDUCTION : 2-Drug Combination Chemotherapy . 2-CdA/VP-16 . INTENSIFICATION : 2-Drug Combination Chemotherapy follow , indicate , Radiotherapy . HD ARA-C/VP-16 ; follow , patient persistent CNS disease , CNS relapse , chloromas , irradiation use megavoltage equipment ( minimum Co60 maximum 6 MV x-rays electron ) . CONSOLIDATION : Regimen A : 2-Drug Combination Chemotherapy . 2-CdA/VP-16 . Regimen B : Myeloablative Chemoradiotherapy follow Hematopoietic Rescue . TBI ( equipment unspecified ) electron boost testis , chest , extramedullary site , , indicate , craniospinal region ; VP-16 ; follow allogeneic autologous bone marrow PBSC . Regimen C : No therapy . PROJECTED ACCRUAL : A total 90 patient enter . The study may close 7 death first 45 patient complete Intensification .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute myeloid leukemia ( AML ) myelodysplastic syndrome one follow category : In first relapse Failed achieve initial complete remission Newly diagnose secondary AML eligible Required bone marrow status : Greater 25 % blast ( M3 ) OR Persistent abnormal clone cytogenetics 525 % blast ( M2 ) No Fanconi 's anemia PATIENT CHARACTERISTICS : Age : Under 22 Performance status : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 1.5 time normal AST ALT less 4.0 time normal Renal : Creatinine great 1.5 time normal OR Creatinine clearance GFR great 70 mL/min per 1.73 square meter GFR equivalent institutional normal range Cardiovascular : Shortening fraction great 27 % echocardiogram institutional normal range OR Ejection fraction great 47 % radionuclide angiogram PRIOR CONCURRENT THERAPY : No 1 prior treatment No prior salvage therapy No prior mitoxantrone</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>